Arbutus Biopharma Corporation ABUS
Set alert
4.21 USD -0.07 -1.64%
At close · Oct 30
4.21 0.00 0.00%
After hours · Oct 30, 4:00 PM ET
4.14 Day range 4.30
3.50 52-week range 5.45
- YTD
- -12.47%
- 1 year
- -13.02%
- Open
- 4.28
- Prev close
- 4.28
- Mkt cap
- 645.29M
- Vol
- 2.53M
- Avg vol
- 4.91M
- EPS
- 0.79
- P/E
- 5.33
- Div yield
- 0.00%
More statistics
- Low
- 4.14
- High
- 4.30
- Forward P/E
- -30.67
- Beta
- 0.62
- Short ratio
- 5.03
- Inst. own
- 72.71%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Nov 16, 2026
- 50-d avg
- 4.79
- 200-d avg
- 4.52
- 1y target
- 5.46
3M chart
Events in this range
- Aug 12, 2026Earnings: -0.03; estimate -0.02; surprise -50%
Signals (15)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 22, 2026 | 1 week ago |
| RSI: Oversold | Oct 12, 2026 | 2 weeks ago |
| RSI: Oversold | Oct 8, 2026 | 3 weeks ago |
| RSI: Oversold | Oct 2, 2026 | 1 month ago |
| SMA: Bearish | Sep 29, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 9, 2026 | 1 month ago |
| SMA: Bullish | Aug 14, 2026 | 2 months ago |
| SMA: Bearish | Aug 12, 2026 | 2 months ago |
| SMA: Bullish | Aug 11, 2026 | 2 months ago |
| SMA: Bearish | Aug 10, 2026 | 2 months ago |
| SMA: Bullish | Aug 7, 2026 | 2 months ago |
| SMA: Bearish | Aug 6, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 6, 2026 | 2 months ago |
| SMA: Bullish | Aug 5, 2026 | 2 months ago |
| SMA: Bullish | Aug 5, 2026 | 2 months ago |
Financial health
Altman Z-Score
30.21 Safe zone
Bankruptcy-risk model: below 1.81 distress, above 2.99 safe.
Piotroski F-Score
5 / 9 Average
Nine pass/fail tests of profitability, leverage and efficiency.
FMP rating
A-4 / 5 overall
- DCF 1
- Return on Equity 5
- Return on Assets 5
- Debt / Equity 4
- P/E 4
- P/B 2
Valuation
P/E -28.3×
FY 2016 5y median -5.7× FY 2025
P/S 65.4×
FY 2016 5y median 37.6× FY 2025
P/B 12.0×
FY 2016 5y median 3.9× FY 2025
P/FCF -23.3×
FY 2016 5y median -9.3× FY 2025
EV/EBITDA -27.5×
FY 2016 5y median -5.6× FY 2025
EV/Sales 64.5×
FY 2016 5y median 29.4× FY 2025
FCF Yield -4.3%
FY 2016 5y median -10.7% FY 2025
Profitability
Gross Margin 97.4%
FY 2016 5y median 100.0% FY 2025
Operating Margin -192.1%
FY 2016 5y median -430.5% FY 2025
Net Margin -237.9%
FY 2016 5y median -401.6% FY 2025
ROE -43.7%
FY 2016 5y median -50.8% FY 2025
ROIC -30.3%
FY 2016 5y median -40.2% FY 2025
ROA -35.4%
FY 2016 5y median -37.3% FY 2025
Growth (YoY)
Revenue 128.2%
FY 2016 FY 2025
Operating Income 64.6%
FY 2016 FY 2025
EPS (diluted) 55.3%
FY 2016 FY 2025
Free Cash Flow 39.1%
FY 2016 FY 2025
Financial Health
Current Ratio 15.7×
FY 2016 5y median 8.2× FY 2025
Quick Ratio 15.7×
FY 2016 5y median 8.2× FY 2025
Debt / Equity 0.1×
FY 2016 5y median 0.1× FY 2025
Net Debt / EBITDA 0.4×
FY 2016 5y median 0.4× FY 2025
Interest Coverage -279×
FY 2016 5y median -170× FY 2025
Dividends
Dividend Yield 0.0%
FY 2016 5y median 0.0% FY 2025
Payout Ratio 0.0%
FY 2016 5y median 0.0% FY 2025
Annual · latest fiscal year ends 2025-12-31